Binding Term Sheet for the Acquisition of ACEA Therapeutics, Inc. by Sorrento Therapeutics, Inc. October 14, 2020Definitive Agreement • February 19th, 2021 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledFebruary 19th, 2021 Company Industry JurisdictionThis Term Sheet (“Term Sheet”) sets forth certain non-binding understandings and certain binding agreements regarding the proposed acquisition of ACEA Therapeutics, Inc. (“ACEA”) by Sorrento Therapeutics, Inc. (“Sorrento”). Collectively ACEA and Sorrento are “Parties”.
LICENSE AGREEMENTLicense Agreement • February 19th, 2021 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledFebruary 19th, 2021 Company Industry JurisdictionThis License Agreement (this “Agreement”) is made as of October 12, 2020 (the “Agreement Date”), by and between Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”) and Personalized Stem Cells, Inc., a Delaware corporation (“PSC”). Sorrento and PSC shall be referred to herein individually as a “Party” and collectively as the “Parties.”